Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on November 11, 2021. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2021. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
No specific material changes or comparative financial data versus prior periods are disclosed in the text of this filing. The document solely references the issuance of the press release containing the results.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors within its text. It explicitly states that the information furnished pursuant to Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the correct registrant name is ReShape Lifesciences Inc., as the input metadata incorrectly listed Vyome Holdings, Inc.
- Review Exhibit 99.1 (Press Release dated November 11, 2021) for actual revenue, net loss, and cash flow figures.
- Confirm the trading symbol RSLS on the Nasdaq Capital Market.
- Note that the financial data in this 8-K is "furnished" and not "filed," limiting its legal liability status under the Exchange Act.